OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-03-31-accounts

Company number: 04397137 Charity number: 1091480

THE HOPE FOUNDATION FOR CANCER RESEARCH

(A COMPANY LIMITED BY GUARANTEE)

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

THE HOPE FOUNDATION FOR CANCER RESEARCH

CONTENTS

__________

Pages
Charity Reference and Administrative Details 3 - 4
Trustees’ Annual Report 5 - 10
Independent Examiner’s Report 11
Statement of Financial Activities (including Income and Expenditure Account) 12
Balance Sheet 13
Statement of Cashflows 14
Notes to the Financial Statements 15 - 24

THE HOPE FOUNDATION FOR CANCER RESEARCH

CHARITY REFERENCE AND ADMINISTRATIVE DETAILS FOR THE YEAR TO 31 MARCH 2024

__________

Charity registration number 1091480
Company registration number 04397137
Patrons Mr Martin Johnson
Mr Lars Tharp
Mr Matt Poole
Presidents Mr David Wyrko
Trustees Mr James Greenlees
Professor Ian Lauder
Mr Rick Moore (Chair)
Mr Duncan Green
Professor Nigel Brunskill
Mr Robert Marsh
Mr Ian Guyler
Ms Kishani Navin (Appointed 23 July 2024)
Co-optee Professor Andreas Gescher
Chief Executive Officer Mr Nigel Rose
Office & Volunteer Manager Mrs Barbara North
Corparate & Community Mr Timothy Gorman-Powell
Partnerships Manager Mr Martin Robinson
Comms & Marketing Manager Mr John Nellis
Registered office Knighton Lodge
208 Knighton Road
Leicester
LE2 3TT
Independent Examiner UHY Hacker Young
14 Park Row
Nottingham
NG1 6GR

CHARITY REFERENCE AND ADMINISTRATIVE DETAILS (CONTINUED) FOR THE YEAR TO 31 MARCH 2024

THE HOPE FOUNDATION FOR CANCER RESEARCH

__________

Bankers HSBC Bank Clock Tower Branch 2-6 Gallowtree Gate Leicester LE1 1DA Investment managers Brewin Dolphin Limited 1[st] Floor Waterfront House Waterfront Plaza 35 Station Street Nottingham NG2 3DQ

THE HOPE FOUNDATION FOR CANCER RESEARCH

TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

The Trustees present their report and the independently examined financial statements of the charity for the year ended 31 March 2024. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” (FRS 102) in preparing the annual report and financial statements of the charity.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.

Trustees of the charity

The directors of the charitable company are its trustees for the purposes of charity law. The trustees who have served during the year and since the year end were as follows:

Mr James Greenlees Professor Ian Lauder Mr Rick Moore (Chair) Mr Duncan Green Professor Nigel Brunskill Mr Robert Marsh Mr Ian Guyler Ms Eileen Richards (Resigned 8 June 2023) Ms Kishani Navin (Appointed 23 July 2024)

Establishment and Objectives

The Hope Foundation for Cancer Research in Leicestershire and Rutland, ‘Hope Against Cancer’ (“the Charity”) was registered as a charity and incorporated as a company limited by guarantee in March 2002.

It was formed in order to provide funding for cancer research projects in Leicestershire and Rutland. The annual report records a further year of achievement of the objects of the Charity. Its objects are:

the promotion and undertaking of research into the causes, property, biology, detection, prevention and treatment of cancer and to publish and disseminate the results of such research;

the relief of pain and suffering of cancer patients through the implementation and improvement of medical and/or surgical procedures through the study of cancer and all its ramifications be they clinical, scientific, psychological, social or economic; and

the encouragement and advancement of innovations for detection and treatment of cancer.

Structure, Governance and Management

The Charity is governed by its Memorandum and Articles of Association dated 18 March 2002 (as amended by a special resolution in 2005 and 2014).

THE HOPE FOUNDATION FOR CANCER RESEARCH

TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

Membership is limited to 14 members who are its trustees and directors (“the trustees”). Trustees, including Chair and Vice-Chair are appointed on three-year terms of service, with potential re-election depending on the governance needs of the Charity.

There is an induction programme for trustees which includes provision of detailed information and a description of roles and responsibilities, register of interests, procedures for meetings, code of conduct, strategic plan and copies of previous reports and minutes.

The Board meets quarterly and makes decisions on research funding with the assistance of the Research Advisory Panel (“ RAP ”), experts in academic and clinical research, who are called upon and convened as and when necessary to advise the wider board on informing the Charity’s research investment decisions. There is regular attendance and reporting from lead professionals in the Leicester Cancer Research Centre and Hope Cancer Trials Centre.

The day to day running of the Charity is delegated to a Chief Executive Officer who manages a small staff team and volunteers.

Achievements and Performance

Research Grants and other funding

In 2023 The Leicester Cancer Research Centre had identified the following priority areas for consideration of funding within the 2023/2024 period, aligning with and supporting its Bio-medical Research Council (“ BRC ”) and Experimental Cancer Medicine Centre (“ ECMC ”) theme objectives, prior to the retirement of Prof Anne Thomas. The following priority areas were identified:

HOPE Research Nurses - £100,000

This is an ongoing salary commitment to support two “HOPE” nurses within the HOPE Cancer Trials Centre, Leicester Royal Infirmary. Contribution to funding of these two nurses helped to support priority areas of growth within the cancer portfolio which align with our Centre strategy. This model has been highly successful with Leicester recruiting a high number to multiple trials and contributing to high impact publications and plenary presentations. This has immediate and highly visible output for the Hope Cancer Trials Centre and Leicester Cancer Research Centre and successes include publications and posters presented at international conferences.

Clinical MD/PhD Studentship – £100,000

The Leicester Cancer Research Centre aims to attract high quality MD/PhD students. They appointed a senior clinical oncology trainee and this award supported the salary of a Clinical Fellow for a second/third year. This clinical research project focused on defining and addressing the barriers to healthcare equity in cancer. As part of this, doctors studied socio-economic, linguistic and other disparities informing patient and research pathways. They led a qualitative study; through establishing appropriate focus groups to hear patient and community voices and experiences, explore barriers and facilitators that may inform trial design and patient engagement and develop intervention strategies.

Risk Management

A risk management programme is in place. The Chair annually consults trustees individually to assist in identifying risks associated with the charity’s activities so as to incorporate appropriate actions into operational plans. A skills audit is used in the appointment of new trustees to ensure that skills required for

THE HOPE FOUNDATION FOR CANCER RESEARCH TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

continuing strategic leadership are available. Induction processes for trustees and volunteers are thorough. All are aware of the responsibilities associated with their role.

Financial procedures are in place to protect cash and investments and risk of theft or fraud is thought to be low. The maintaining of unrestricted reserves at an agreed level will provide sufficient resource in the event of loss of voluntary income. An ‘investment sub-committee’ has been formed which includes the Chief Executive and two trustees with thorough investment and financial planning skills and experience to monitor and review investments and make recommendations to the full Board.

Volunteer training programmes are on-going and volunteer recruitment, retention and development policies are regularly reviewed.

Regular contact is maintained with researchers to ensure that the funds are spent in accordance with the conditions attached to each grant made. Grant application processes and reporting and monitoring arrangements have been reviewed to ensure fitness for the major investments into the centre of excellence partnership for the medium term (3-5 years).

IT backup and protection systems are in place and maintained. A database and cloud-based server to optimise customer relationship management and modernise secure data storage is operating. Property tenure has been secured with our partners at the University of Leicester and is reviewed annually.

Impact

The Charity’s strategy is to work in partnership with local universities and hospitals to ensure that Leicestershire remains a centre of excellence for cancer research and treatment to achieve the greatest impact in the local and national fight against cancer. With public support and the support of public sector and charity partners, we have helped to achieve the following:

The Leicester Cancer Research Centre (“ LCRC ”) is part of the College of Life Sciences at the University of Leicester led by Pro-Vice-Chancellor, Head of College, Professor Tom Robinson. It is a partnership that now rivals those of major cancer research hubs in much larger cities. The LCRC is internationally recognised for their research in key areas including treatment of hematological malignancies, precision therapeutics for mesothelioma, pre-clinical models for drug discovery, cancer prevention and the liquid biopsy for cancer detection.

Their mission is to facilitate world-leading bench-to-bedside research in cancer prevention, early detection, and cutting-edge treatments for solid tumours and hematological malignancies. This is underpinned by a strong focus on translational research studies and delivered via patient-centred approaches to transform outcomes for patients with cancer or at risk of cancer.

Key staff include 14 senior professors who are University Academics, 24 researchers, 33 professional services staff and 28 research students. Many staff are experts involved in the Leicester Precision Medicine Centre, one of five research institutes.

The funding that continues to be awarded to support vital equipment, nursing staff, PhD studentships, and pump-priming development awards is vital. The benefit of this to researchers and patients is evidenced by the papers they have produced and the additional funding they have leveraged. In addition, training of the researchers of the future has been brilliantly supported too. The funding they have received from Hope has allowed them to obtain vital preliminary data for publications and subsequent grant applications.

THE HOPE FOUNDATION FOR CANCER RESEARCH TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

These are just some of the outcomes deemed successful post-Hope Funding. In addition, the Experimental Cancer Medicine Centre (“ ECMC ”) renewal was in large part successful due to the continuation and ongoing support of Hope funding for the research nurses. Many competitive bidding processes favour or even require applications to include a credible local partner who will be meaningfully involved in delivering projects. The Centre’s application to embed cancer as a new Theme in the BRC NIHR bid was successful! This is a prestigious award which will transform the infrastructure and research capability.

Financial Review

During the year the Charity has received income of £428,845.

The Charity spent a total of £524,770, including grants to the value of £130,000 were funded.

At the year end liquid funds of £1,342,796 (2023: £1,464,069) were held.

Brewin Dolphin Limited has acted as discretionary investment managers to take care of the share portfolio valued at the year end at £463,653 in accordance with the charity’s Investment Policy.

Public Benefit

The trustees have monitored the way in which Charity funds are expended and consider that this is in line with the objects of the charity and for the benefit of the public. The Charity’s main objective is to fund cancer research that saves lives or improves the quality of life through earlier diagnosis, prevention or better treatment of cancer. This brings significant public health benefits to local communities.

The directors consider that they have complied with their duties under the Charities Act 2011 to have due regard to public benefit guidance published by the Charities Commission.

Fundraising Regulator

The Charity participates in the Fundraising Regulator’s voluntary regulation scheme. The trustees consider the Charity has complied with The Code of Fundraising Practice as outlined on the Fundraising Regulator’s website at www.fundraisingregulator.org.uk/code.

Reserves Policy

The basic requirement of the reserves policy is to maintain free reserves, in unrestricted general funds, at a level which ensures that the charity will be able to meet at least six months committed expenditure, including event costs as well as funding grants which will arise in the coming year.

The Trustees are satisfied that the unrestricted and undesignated general funds at the year-end of £1,419,050 are appropriate. However it remains vital that we continue to raise funds to support cancer research.

Plans for the future

The Trustees will continue to support the Hope Cancer Trials Centre which is an internationally-renowned and recognised research environment and will remain central to helping ensure continued success of all the Centre’s national grant bids, leveraging income from national institutions and funding bodies, to be spent locally and regionally on the research efforts here.

THE HOPE FOUNDATION FOR CANCER RESEARCH TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

HOPE will also continue to respond to planned and timed annual funding requests that support the strategy of the LCRC, including some development projects, funding vital medical research equipment that hekps speed up progress of research.

Acknowledgements

The Board acknowledges and thanks all its volunteers, generous corporate sponsors and individual supporters and donors. It thanks the University of Leicester for providing the Charity’s office accommodation.

Trustees’ responsibilities

The trustees (who are also directors of The Hope Foundation for Cancer Research for the purposes of company law) are responsible for preparing the Trustees’ Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

THE HOPE FOUNDATION FOR CANCER RESEARCH

TRUSTEES’ ANNUAL REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR TO 31 MARCH 2024

__________

Disclosure of information to the independent examiners

We, the directors of the company who held office at the date of approval of these Financial Statements as set out above each confirm, so far as we are aware, that:

On behalf of the board

Mr Rick Moore Chair of the Board of Trustees

Date: ………………………..

Company Registration number: 04397137 Charity number: 1091480

THE HOPE FOUNDATION FOR CANCER RESEARCH

INDEPENDENT EXAMINER’S REPORT FOR THE YEAR TO 31 MARCH 2024

__________

I report on the accounts of the company for the year ended 31 March 2024 which are set out on pages 12 to 24.

Respective responsibilities of trustees and examiner

As the charity’s trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (the ‘2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner’s report

Since the company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe:

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Chris McKain FCA UHY Hacker Young Chartered Accountants

Date: ………………………..

THE HOPE FOUNDATION FOR CANCER RESEARCH

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR TO 31 MARCH 2024

__________

Note
Income from:
Voluntary income
2
Investment income
3
Total income and endowments
Expenditure on:
Generating funds
4
Charitable activities
6
Total expenditure
Net expenditure
Net gains / (losses) on investments
11
Net movement in funds
15
Reconciliation of funds:
Total funds brought forward
15
Total funds carried forward
15		 2024
Unrestricted
Funds
£
391,304
37,541
428,845
394,770
130,000
524,770
(95,925)
19,671
(76,254)
1,419,050
1,342,796		 2023
Unrestricted
Funds
£
524,754
15,633
540,387
320,553
350,000
670,553
(130,166)
(35,353)
(165,519)
1,584,569
1,419,050

All income and expenditure derive from continuing activities.

The statement of financial activities includes all gains and losses recognised during the year.

The notes on pages 15 to 24 form part of these financial statements.

THE HOPE FOUNDATION FOR CANCER RESEARCH

BALANCE SHEET FOR THE YEAR TO 31 MARCH 2024

__________

Note
Fixed assets
Tangible assets
10
Investments
11
Current assets
Debtors
12
Cash at bank and in hand
Creditors: amounts falling due within
one year
13
Net current assets
Total assets less current liabilities
Creditors: amounts falling due after
more than one year
Net assets
Charity Funds
Unrestricted funds
15
Total charity funds
15		 £
12,795
1,331,473		 2024
£
-
463,653
463,653
879,143
1,342,796
-
1,342,796
1,342,796
1,342,796		 £
10,696
1,464,069		 2023
£
-
446,432
446,432
972,618
1,344,268
(465,125)		 1,474,765
(502,147)
1,419,050
-
1,419,050
1,419,050
1,419,050

For the financial year ended 31 March 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of its accounts for the year ended 31 March 2024 in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibility for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies’ regime. The financial statements were approved and authorised for issue by the Board on………………………

Signed on behalf of the board of trustees by:

Mr Rick Moore Chair of the Board of Trustees Company Registration number: 04397137 Charity number: 1091480

The notes on pages 15 to 24 form part of these financial statements.

THE HOPE FOUNDATION FOR CANCER RESEARCH

STATEMENT OF CASH FLOWS FOR THE YEAR TO 31 MARCH 2024

__________

Cash and cash equivalents consists of:
Current account
Money market deposits
Broker’s account
Deposit account
Charity bonds
Cash at bank and in hand at 31 March
Note
Cash flow from operating activities
16
Net cash flow from operating activities
Cash flow from investing activities
Payments to acquire investments
Receipts from sales of investments
Interest received
Dividends received
Net cash flow from investing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at 1 April
Cash and cash equivalents at 31 March		 16,445
815,901
14,172
279,284
205,671
1,331,473
2024
£
(172,587)
(172,587)
(96,836)
99,286
27,463
10,078
39,991
(132,596)
1,464,069
1,331,473		 2023
£
(715,357)
(715,357)
(283,516)
284,993
7,472
8,161
14,156
(701,201)
2,166,728
1,464,069
9,851
968,006
12,168
272,947
201,097
1,464,069

The notes on pages 15 to 24 form part of these financial statements.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

1 Summary of significant accounting policies

(a) General information and basis of preparation

The Hope Foundation for Cancer Research is a company limited by guarantee registered in England & Wales and a registered charity in England. The address of the registered office is given in the charity reference and administrative details on page 3 of these financial statements. The nature of the charity’s operations and principal activities are outlined on page 5.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Practice.

The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

(b) Funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. No such funds are currently held.

(c) Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

For donations to be recognised the charity will have been notified of the amounts and the settlement date in writing. If there are conditions attached to the donation and this requires a level of performance before entitlement can be obtained then income is deferred until those conditions are fully met or the fulfilment of those conditions is within the control of the charity and it is probable that they will be fulfilled.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received. At this point income is recognised. On occasion legacies will be notified to the charity however it is not possible to measure the amount expected to be distributed. On these occasions, the legacy is treated as a contingent asset and disclosed.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes such as shares. It includes dividends and interest. Interest income is recognised using the effective interest method and dividend income is recognised as the charity’s right to receive payment is established.

(d) Gifts in kind

The charity benefits from many hours given freely by trustees, patrons and other volunteers. The charity is extremely grateful for all these gifts in kind. It is extremely difficult to place a value on the time gifted and accordingly, this not included within the Statement of Financial Activities.

(e) Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties. It is categorised under the following headings:

Grants payable to third parties are within the charitable objectives. Where unconditional grants are offered, this is accrued as soon as the recipient is notified of the grant, as this gives rise to a reasonable expectation that the recipient will receive the grants. Where grants are conditional relating to performance then the grant is only accrued when any unfulfilled conditions are outside of the control of the charity.

(f) Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. Cost includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Fixtures and fittings 20% straight line Computer equipment 33% straight line

All assets with a value less than £1,250 are written off in the year in which they are acquired.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

(g) Investments

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value with changes recognised in ‘net gains / (losses) on investments’ in the SoFA if the shares are publicly traded or their fair value can otherwise be measured reliably.

(h) Taxation

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

2 Voluntary income

General donations
Events
In memoriam
Regular giving
University of Leicester
Greetings cards
Books
Tax refund
untary income received in 2023 and 2024 is unrestricted.
nvestment income
Bank interest
Share dividends		 2024
£
251,987
82,072
11,393
6,564
8,472
-
896
29,920
391,304
2024
£
27,463
10,078
37,541		 2023
£
247,318
207,944
21,168
7,544
8,472
663
245
31,400
524,754
2023
£
7,472
8,161
15,633

All voluntary income received in 2023 and 2024 is unrestricted.

3 Investment income

All investment income received in 2023 and 2024 is unrestricted.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

4 Cost of generating funds

Note
General costs
5
Events
Capital development costs
5
Analysis of general costs
Staff costs
Staff and volunteer training
Staff and volunteer recruitment
Equipment
Utilities
Postage and stationery
Telephone and internet charges
Insurance
Marketing
Travel expenses
Bank charges
Subscriptions
Miscellaneous
Administrative costs
Legal and professional fees
Hopeful Futures		 2024
£
255,884
57,114
81,772
394,770
2024
£
174,012
1,263
1,951
14,275
4,022
4,581
1,659
1,846
31,718
2,770
903
3,047
4,002
8,635
1,200
-
255,884		 2023
£
231,682
88,477
394
320,553
2023
£
157,503
96
-
11,447
1,900
4,669
1,741
1,756
29,434
2,628
739
2,651
4,799
10,222
1,200
897
231,682

Essentially all costs incurred relate to fundraising for the charity and are unrestricted for both 2023 and 2024. Within the costs for the year a total of £81,772 (2023: £394) was in relation to the designated fund for a capital project.

6 Charitable activities

haritable activities
2024 2023
Note £ £
Grants awarded 7 130,000 350,000

All grants awarded for 2023 and 2024 are unrestricted.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

7 Analysis of grants

Period of
award
CTF Nurse 2022/23
2022/2023
CTF Nurse 2022/23 additional
2022/2023
CTF Nurse 2023/24
2021/2023
CTF Nurse 2024/25
2024/2025
LCRC – 2021/22
2021/2022
Precision Cancer Theme Support
2022/2023
Clinical PhD Fellowships
2022/2023		 2024
£
-
-
-
100,000
30,000
-
-
130,000		 2023
£
9,000
41,000
100,000
-
-
100,000
100,000
350,000

Amounts awarded to date but still due for payment totalled:

Dr Chris Talbot
(Breast Cancer)
Dr Lynn Furber
(Breast Cancer)
CTU Nurse 2022/23
LCRC- 2021/22
CTU Nurse 2023/24
CTU Nurse 2024/25
Precision Cancer
Theme Support
Clinical PhD
Fellowships		 2024
Due
within one
year
Due after
more than
one year
Total due
£
£
£
-
-
-
15,680
-
15,680
1,005
1,005
29,464
-
29,464
100,000
-
100,000
100,000
-
100,000
100,000
-
100,000
100,000
-
100,000
446,149
-
446,149		 2023
Due
within one
year
Due after
more than
one year
Total due
£
£
£
3,013
-
3,013
15,680
-
15,680
90,000
90,000
74,474
-
74,474
100,000
-
100,000
-
-
-
100,000
-
100,000
100,000
-
100,000
483,167
-
483,167

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

8 Trustees' and key management personnel remuneration and expenses

The trustees neither received nor waived any remuneration during the year (2023: £Nil).

The trustees did not have any expenses reimbursed during the year (2023: £Nil).

The total amount of employee benefits received by key management personnel is £62,694 (2023: £60,868). The charity considers its key management personnel to be the Chief Executive Officer.

9 Staff costs and employee benefits

The charity relies on the services of 5 (2023: 4) employees.

The total cost of these individuals in the year was £174,012 (2023: £157,503).

One employee received total employee benefits (excluding employer pension costs) within the range £60,000 to £69,999 (2023: one).

10 Tangible fixed assets

Cost or valuation:
At 1 April 2023 & 31
March 2024
Depreciation:
At 1 April 2023 & 31
March 2024
Net book value:
At 31 March 2023
At 31 March 2024		 Fixtures
and fittings
£
4,803
4,803
-
-		 Computer
equipment
£
5,448
5,448
-
-		 Total
£
10,251
10,251
-
-

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

11 Fixed asset investments

Market value at 1 April
Acquisitions at cost
Sales proceeds from disposals
Net gains / (losses) on revaluation in the year
Market value at 31 March
Historical cost as at 31 March
Investments at fair value compromise:
Listed investments in the UK
Listed investments outside the UK		 2024
£
446,432
96,836
(99,286)
19,671
463,653
435,616
2024
£
168,467
295,186
463,653		 2023
£
483,262
283,516
(284,993)
(35,353)
446,432
436,024
2023
£
135,701
310,731
446,432

Listed investments held outside the UK include shares held in Guernsey which the trustees consider to be an inactive market. The shares have been valued at the traded value nearest to the year end as, in the opinion of the trustees, this fairly reflects the value of shares at 31 March 2024. All other investments have been valued at the market value at 31 March 2024.

12 Debtors

12
Debtors
Prepayments and accrued income
13
Creditors: amounts falling due within one year
Other tax and social security
Accruals for grants payable (Note 7)
Accruals
Deferred income (Note 14)		 2024
£
12,795
2024
£
3,368
446,149
4,047
11,561
465,125		 2023
£
10,696
2023
£
4,403
483,167
2,979
11,598
502,147

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

14 Deferred income

eferred income
At 1 April 2023
Additions during the year
Amounts released to income
At 31 March 2024		 2024
£
11,598
11,561
(11,598)
11,561		 2023
£
50,408
1,500
(40,308)
11,598

Income has been deferred as it relates to events held after the year end.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

15 Fund reconciliation

2024

024
Undesignated
Designated
Unrestricted		 Balance
at 1 April
2023
Income
Expenditure
Gains on
investments
Balance at
31 March
2024
£
£
£
£
£
855,442
428,845
(442,998)
19,671
860,960
563,608
-
(81,772)
-
481,836
1,419,050
428,845
(524,770)
19,671
1,342,796

£59,351 of the 2024 unrestricted funds are designated for a project to obtain additional donors.

£422,485 of the 2024 unrestricted funds are designated for a capital appeals fund for a major and ambitious expansion project at the Hope Clinical Trials Facility at Leicester Royal Infirmary.

2023

Undesignated
Designated
Unrestricted		 Balance
at 1 April
2022
Income
Expenditure
Losses on
investments
Balance at
31 March
2023
£
£
£
£
£
1,020,567
540,387
(670,159)
(35,353)
855,442
564,002
-
(394)
-
563,608
1,584,569
540,387
(670,553)
(35,353)
1,419,050

£59,351 of the 2023 unrestricted funds are designated for a project to obtain additional donors.

£504,257 of the 2023 unrestricted funds are designated for a capital appeals fund for a major and ambitious expansion project at the Hope Clinical Trials Facility at Leicester Royal Infirmary.

THE HOPE FOUNDATION FOR CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR TO 31 MARCH 2024

__________

16 Reconciliation of net expenditure to net cash flow from operating activities

Deficit for the year
Interest received
Dividends received
Fair valuation of investment
(Increase)/decrease in debtors
Decrease in creditors due within one year		 2024
£
(76,254)
(27,463)
(10,078)
(19,671)
(2,099)
(37,022)
(172,587)		 2023
£
(165,519)
(7,472)
(8,161)
35,353
18,883
(588,441)
(715,357)

17 Related party transactions

There are no related party transactions during the period (2023: £Nil).